Displaying drugs 10276 - 10300 of 12422 in total
BLX-883
BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide sales currently exceed $3 billion.
Investigational
Matched Description: … BLX-883 is a form of alfa interferon developed by Biolex for the treatment of hepatitis viral C. ... Alfa interferon is used in the treatment of hepatitis C, hepatitis B, and multiple cancers and its worldwide …
Baicalein
Baicalein is under investigation in clinical trial NCT03830684 (A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever).
Investigational
Matched Description: … Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever). ... Double-blind, Placebo-controlled, Multicenter and Phase ⅡA Clinical Trial for the Effectiveness and Safety of …
Dianexin
Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin in Kidney Transplant Recipients).
Investigational
Matched Description: … Dianexin is under investigation in clinical trial NCT00615966 (Phase 2 Study of the Safety of Diannexin …
Terevalefim
Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney).
Investigational
Matched Description: … of a Deceased Donor Kidney). ... Terevalefim is under investigation in clinical trial NCT02474667 (Reduce the Severity of DGF in Recipients …
Etavopivat
Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for the treatment of sickle cell disease.
Investigational
Matched Description: … the treatment of sickle cell disease. ... Etavopivat is a small molecule activator of erythrocyte pyruvate kinase (PKR) under investigation for …
UV1
UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments of the hTERT subunit
Investigational
Matched Description: … of the hTERT subunit ... UV1 is a cancer vaccine consisting of p719-20, p728, and p725 synthetic peptides representing fragments …
Varlitinib
Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR. Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and epidermal carcinoma tumors.
Investigational
Matched Description: … Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients ... Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 ... Varlitinib has shown significant anti-tumor activity in preclinical models of human breast, lung, and …
PF-05241328
PF-05241328 is under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not Have Any Pharmacological Activity).
Investigational
Matched Description: … Compound in and Rate of Excretion From the Blood) Following a Very Low Dose of Compound Which Will Not ... under investigation in clinical trial NCT01165736 (To Calculate the Pharmacokinetics (Concentration of …
Afimoxifene
Afimoxifene (4-Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of estrogen-dependent conditions, including cyclic breast pain and gynecomastia. TamoGel is formulated using Enhanced Hydroalcoholic Gel (EHG) Technology. This technology enables percutaneous delivery of drugs that cannot be delivered orally. It is being developed by...
Investigational
Matched Description: … This technology enables percutaneous delivery of drugs that cannot be delivered orally. ... Hydroxytamoxifen, trade name TamoGel) is a new estrogen inhibitor under investigation for a variety of …
PTI-801
PTI-801 represents a new class of drugs to treat pain. PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone. It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist.
Investigational
Matched Description: … PTI-801 represents a new class of drugs to treat pain. ... It is a combination of oxycodone with ultralow-dose naltrexone, an opioid antagonist. ... can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of …
Fucoxanthin
Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). Fucoxanthin isis a marine carotenoid mainly found in brown algae, giving them a brown or olive-green color. Fucoxanthin is investigated for its anti-inflammatory, antinociceptive and anti-cancer effects....
Investigational
Matched Description: … action of fucoxanthin is not fully elucidated. ... an animal model of duodenal, skin, colon and liver cancer. ... of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion). …
Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was developed using domains of viral structural proteins and a polyprotein protease. Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, and with the described approach, the vaccine uses these...
Investigational
Matched Description: … Through analysis of potential immunogenic targets of the SARS-Cov2 genome, a synthetic ‘minigene’ was ... developed using domains of viral structural proteins and a polyprotein protease. ... Specifically, the COVID-19 infection relies on the binding of the Spike protein to an ACEII receptor, …
Pegamotecan
Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue, and Gastroesophageal Cancer.
Investigational
Matched Description: … Pegamotecan has been used in trials studying the treatment of Cancer of Stomach, Sarcoma, Soft Tissue …
Aganirsen
Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG).
Investigational
Matched Description: … at Risk of Developing NVG). ... Aganirsen is under investigation in clinical trial NCT02947867 (Trial of Aganirsen in iCRVO Patients …
RDEA806
RDEA806 is a new HIV non-nucleoside reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of activity.
Investigational
Matched Description: … reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to resistance and a broad spectrum of …
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)-
Isoquinoline, 7-(2-(3,6-dihydro-4-(3-(trifluoromethyl)phenyl)-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid Arthritis).
Investigational
Matched Description: … Oral Administration of SSR150106XB for the Reduction of Inflammation in Patients With Active Rheumatoid ... )-1(2h)-pyridinyl)ethyl)- is under investigation in clinical trial NCT00545454 (Activity and Safety of …
BacTRL-spike
BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum engineered to deliver synthetic DNA encoding spike protein from SARS-CoV-2 contained by plasmids. The vaccine was developed by Symvivo Corporation. As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled Trial (NCT04334980) to...
Investigational
Matched Description: … BacTRL-Spike is composed of a bacterial medium with colony-forming-units of live Bifidobacterium longum ... Trial (NCT04334980) to test the safety and immunogenicity of the vaccine. ... As of June, 2020, the company is pursuing a Phase 1, Randomized, Observer-Blind, Placebo-Controlled …
Endothelin-1
Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation on Vascular Function - the Role of Endothelin).
Investigational
Matched Description: … on Vascular Function - the Role of Endothelin). ... Endothelin 1 is under investigation in clinical trial NCT00745693 (The Effects of Diesel Exhaust Inhalation …
Proscillaridin
Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima (Scilla maritima). Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence of the drug potently disrupting topoisomerase I and II activity at nanomolar drug concentrations and triggering cell...
Experimental
Matched Description: … ] and triggering cell death and blocking cell proliferation of glioblastoma cell lines [A27194]. ... Proscillaridin is a cardiac glycoside that is derived from plants of the genus Scilla and in Drimia maritima ... Studies suggest the potential cytotoxic and anticancer property of proscillaridin, based on evidence …
ORG-34517
ORG-34517 is currently under investigation by Organon for the treatment of depression. It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma etc, in which the activity of metabolites corticosterone and cortisol is high.
Investigational
Matched Description: … etc, in which the activity of metabolites corticosterone and cortisol is high. ... ORG-34517 is currently under investigation by Organon for the treatment of depression. ... It has potential to treat a number of diseases such as Cushing’s disease, hypertension, diabetes, glaucoma …
DLO6002
DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Investigational
Matched Description: … DLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of …
Romilkimab
Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in the Treatment of Idiopathic Pulmonary Fibrosis).
Investigational
Matched Description: … the Treatment of Idiopathic Pulmonary Fibrosis). ... Romilkimab is under investigation in clinical trial NCT02345070 (Efficacy and Safety of SAR156597 in …
Sibofimloc
Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence of Postoperative Crohn's Disease (CD)).
Investigational
Matched Description: … of Postoperative Crohn's Disease (CD)). ... Sibofimloc is under investigation in clinical trial NCT03943446 (TAK-018 for Prevention of the Recurrence …
Ianalumab
Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 in Patients With Pemphigus Vulgaris).
Investigational
Matched Description: … Ianalumab is under investigation in clinical trial NCT01930175 (Study of Efficacy and Safety of VAY736 …
(1R,2S)-2-Phenylcyclopropanaminium
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311)
Experimental
Matched Description: … A propylamine formed from the cyclization of the side chain of amphetamine. ... This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder …
Displaying drugs 10276 - 10300 of 12422 in total